Image de couverture de livre

Canagliflozin Alleviates Metabolic Dysfunction‐Associated Steatotic Liver Disease via Mitochondrial Protection and Enhanced Mitophagy

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ming Lu, Yixin Zhao, Zhihong Liu, Yanrong Zhang, Jing Liu
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Hepatology Research
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Oguzhan Celik, et autres
Publié: (2026)

Response to “Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
par: Tsubasa Tsutsumi, et autres
Publié: (2026)

Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis
par: Iulia Minciuna, et autres
Publié: (2025)

Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption
par: Jesse Pustjens, et autres
Publié: (2025)

Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake
par: Tomomi Kogiso, et autres
Publié: (2025)

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026
par: Norio Akuta, et autres
Publié: (2026)

Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
par: Dong Wook Kim, et autres
Publié: (2025)

Fibrosis‐4 Index as a Robust Long‐Term Predictor of Cancers in Metabolic Dysfunction–Associated Steatotic Liver Disease
par: Ayumi Kanamoto, et autres
Publié: (2026)

From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell‐free DNA in Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Wei‐Yue Lim, et autres
Publié: (2026)

Steatotic Liver Disease and the “Point of No Return” in the Development of Metabolic Disorders
par: Tsutomu Nishida, et autres
Publié: (2026)

Association Between Liver Fibrosis and Cause‐Specific Mortality in Japanese Patients With Biopsy‐Confirmed Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD
par: Kyoko Sakai, et autres
Publié: (2025)

Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma
par: Kenji Imai, et autres
Publié: (2025)

Response to “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
par: Kenji Imai, et autres
Publié: (2026)

Response to the Letter “Steatotic Liver Disease and the ‘Point of No Return’ in the Development of Metabolic Disorders”
par: Yoshihiro Kamada
Publié: (2026)

Letter to the Editor: “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
par: Lixia Yao, et autres
Publié: (2025)

Vitamin E in Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Stergios A. Polyzos, et autres
Publié: (2024)

Letter to the Editor: Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders
par: Jianing Hou, et autres
Publié: (2026)

Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders
par: Yoshihiro Kamada, et autres
Publié: (2025)

The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
par: Jae Eun So, et autres
Publié: (2025)

Comment on “Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
par: Hong‐Wei Zheng, et autres
Publié: (2026)

Response to the Letter “Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders”
par: Yoshihiro Kamada
Publié: (2026)

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction–Associated Steatotic Liver Disease
par: Meng‐Lun Hsieh, et autres
Publié: (2026)

Toward a Synthetic Data Revolution: Diffusion Model‐Enhanced Hepatocellular Carcinoma Prediction in Steatotic Liver Disease
par: Masaya Sato, et autres
Publié: (2026)

Loss of Posterior Occlusal Support Is Associated With Incident Steatotic Liver Disease in a Nationwide Longitudinal Analysis of the JMDC Claims Database
par: Takashi Miyano, et autres
Publié: (2026)

Comment on “Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
par: Klara Morzone, et autres
Publié: (2026)

A Novel Fibroblast Activation Protein‐Based Algorithm to Assess Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
par: Ziqi V. Wang, et autres
Publié: (2026)

Epidemiology of Metabolic Dysfunction–Associated Steatotic Liver Disease in South Asian Ethnicities: A Systematic Review and Meta‐Analysis
par: Michael James, et autres
Publié: (2025)

Comment on: “Epidemiology and Clinical Characteristics of Fatty Pancreas Disease in Metabolic Dysfunction‐Associated Steatotic Liver: A Systematic Review”
par: Isheeka Lohana, et autres
Publié: (2026)

Metabolic‐Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
par: John Cooper, et autres
Publié: (2025)

The Impact of Inflammatory Markers on Prognosis in Advanced Chronic Liver Disease: Insights From a Prospective Cohort Study
par: Jing Liu, et autres
Publié: (2025)

Response to the Letter Regarding “Epidemiology and Clinical Characteristics of Fatty Pancreas Disease in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Systematic Review”
par: Luan C. V. Lima, et autres
Publié: (2026)

Guidance for Liver Rehabilitation in Chronic Liver Disease
par: Shuji Terai, et autres
Publié: (2026)

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis
par: Hayato Kawamura, et autres
Publié: (2025)

Imaging‐Based Surveillance of Gastroesophageal Varices in Fontan‐Associated Liver Disease: Toward a Noninvasive Strategy
par: Tadashi Namisaki, et autres
Publié: (2025)

Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
par: Takashi Motomura, et autres
Publié: (2026)

Impact of Smoking Cessation Attempts on Outcomes in Metabolic Dysfunction–Associated Steatotic Liver Disease: A Large Propensity Score–Matched Cohort Study
par: Mohammad Alabbas, et autres
Publié: (2026)

Variability in Liver Disease Progression and Outcomes in Glycogen Storage Disease Type IV
par: Rebecca L. Koch, et autres
Publié: (2026)

Elevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease
par: Motoh Iwasa, et autres
Publié: (2025)

Diagnostic Performance of Serum Autotaxin for Staging Liver Fibrosis: A Comparative Study With Other Noninvasive Liver Fibrosis Tests in Chronic Liver Disease
par: Hideyuki Tamai, et autres
Publié: (2025)

Machine Learning Models to Predict Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) With Simple Anthropometric and Biochemical Variables: A Cross‐Sectional Study in US Population
par: Shiying Du, et autres
Publié: (2026)